Americans also want to know why american ceos and executives continue t basic responsibility that theydeaths every day of the year in this country. And that was representative mike synar, a democrat of oklahoma. In 1994, at a highly publicized hearing on tobacco. And this week on our series. Congress investigates. Well, it was in april of 1994 that ceos Tobacco Companies went before congress as part of an investigation into Health Hazards posed by their products. Hour hearing was controversial. And it led to toopanies admitting their products were addictive. Industry followed. Joining us fhe tobacco debate and the 1994 hearings is elise payne, director of the d. C. Office of the levin center for oversight and democracy. Elise bean we had been debating the impact of Tobacco Products for decades. By that point. About 1994 that brought this all together . Well, i think the key was an announcement by the food and Drug Administration. And commis kessler that they had evidence that the Tobac
In the continuing effort to improve upon opioid pain relievers, American and Chinese scientists used cryoEM technology to solve the detailed structures of the entire family of opioid receptors bound to their naturally occurring peptides.
Scientists Take Another Step Toward Creating Better Pain Medications miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to highlight an independent research review published in the January 5 th edition of the European Archives of Psychiatry and Clinical Neuroscience that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19. The Review focuses on the sigma-1 receptor in the endoplasmic reticulum, a …
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to highlight an independent research review (the “Review”) published in the January 5 th edition of the European Archives of Psychiatry and Clinical Neuroscience that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19.